Overview of Granocyte 34

Quick Facts

Property	Description
Active Ingredient	Lenograstim (rHuG-CSF)
Pharmaceutical Form	Solution for injection or infusion
Pharmacological Class	Hematopoietic growth factor (G-CSF)
Origin	Biotechnology-derived (Recombinant, glycosylated protein)
General Purpose	To stimulate neutrophil production

Granocyte 34 is a biological medicine whose active substance is Lenograstim, which is classified as a Hematopoietic growth factor, specifically a Granulocyte Colony-Stimulating Factor (G-CSF). Lenograstim is a recombinant human protein manufactured using biotechnology-derived methods. A key differentiating feature of Lenograstim is its glycosylation—a structural modification that makes it highly analogous to the naturally occurring G-CSF protein in the human body, a quality often noted in pharmacological comparisons.

Origin and Physical Form of Lenograstim

Lenograstim’s mechanism involves the specific stimulation of progenitor cells in the bone marrow, a process recognized for supporting immune system function. Granocyte 34 is supplied for direct systemic administration as a sterile solution for injection or infusion, or as a powder for reconstitution. This delivery method is essential because the active ingredient, being a large protein molecule, must be administered parenterally (via subcutaneous injection or intravenous infusion) to bypass destruction in the digestive system.

General Purpose: What Does Granocyte 34 Help to Achieve?

The primary function of Lenograstim is to accelerate granulopoiesis, which is the process of generating infection-fighting white blood cells. This action is crucial in scenarios where the body's neutrophil count is compromised. G-CSFs function by providing a rapid, targeted boost to the immune system, primarily by shortening the time required to restore the patient's neutrophil levels and thereby improving recovery. This medicine provides a vital, targeted boost to the body's defense system.

What side effects are possible with Granocyte 34?

Possible side effects and safety information

Regulatory documents classify the adverse reactions associated with Lenograstim (Granocyte 34) based on frequency and the body system affected. The safety information details both common, expected effects and uncommon, clinically significant reactions, as officially documented by government health authorities.

Adverse Reaction Classification

The most frequently documented events, classified as Very Common (ge 1/10), include musculoskeletal pain (such as bone pain) and leucocytosis (an increase in white blood cells). Common (ge 1/100 to < 1/10) adverse reactions involve a temporary decrease in platelet count, known as transient thrombocytopenia.

Adverse reactions that are classified as Uncommon (ge 1/1,000 to < 1/100) include splenic rupture, acute respiratory distress syndrome (ARDS), and specific skin conditions such as Sweet's syndrome or cutaneous vasculitis. Rarer events, such as aortitis, are also listed in regulatory texts.

System-Organ Class Involved	Example Adverse Reactions	Frequency Tier Example
Musculoskeletal and Connective Tissue	Bone pain, Musculoskeletal pain	Very Common
Blood and Lymphatic System	Splenic rupture, Thrombocytopenia	Uncommon / Common
Respiratory, Thoracic, Mediastinal	ARDS, Dyspnoea	Uncommon

Safety Patterns and Restrictions

Safety statements note that musculoskeletal effects may be more prominent at the beginning of treatment (initial doses). Safety discussions concerning the potential for secondary myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) are addressed in the context of specific underlying conditions and potential long-term exposure.

Official regulatory restrictions state that the medicine is contraindicated in individuals with a known hypersensitivity to the active substance or excipients, and in those with myeloid malignancy other than de novo acute myeloid leukaemia in specific settings. Use is also restricted immediately before or after cytotoxic chemotherapy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Granocyte 34 (Lenograstim) describes the primary concern in the event of an overdose as the potential for an exaggerated pharmacological effect. The central physiological manifestation of overdosage is severe leukocytosis, which is a potentially life-threatening overproduction of white blood cells. Regulatory labeling defines specific thresholds for intervention, such as white blood cell counts exceeding 50 imes 10^9/L or 70 imes 10^9/L.

Symptoms documented at high-dose exposures include musculoskeletal pain, specifically bone pain and muscle pain, which were the only toxic effects observed at doses significantly above the standard therapeutic range.

In all cases of suspected overdosage, regulatory authorities mandate that immediate medical attention must be sought. Patients must contact emergency services or go to the nearest Accident and Emergency department even if there are no signs of discomfort or poisoning.

The official management procedure upon detection of severe leukocytosis is the immediate discontinuation of Granocyte 34 therapy and the provision of symptomatic and supportive treatment. Regulatory documents state that no specific antidote has been established for Lenograstim.

Therapeutic Uses of Granocyte 34

What Granocyte 34 Treats: Main Uses and Benefits

Granocyte 34 (Lenograstim) is commonly used to provide supportive relief in clinical settings involving temporary physiological imbalance and immune strain. Its use helps with assisting with the production of infection-fighting white blood cells (neutrophils) to support the body's defenses. The medication is applied across domains where additional symptomatic support is needed.

The medication is relevant in conditions characterized by periods of heightened symptoms after intensive treatments like chemotherapy or bone marrow/stem cell transplantation, as well as for mobilizing stem cells. The primary therapeutic benefit contributes to easing the overall symptom burden during the recovery period, which may assist with maintaining functional stability.

Granocyte 34 supports the patient during difficult episodes by addressing the risks associated with low neutrophil counts, particularly severe neutropenia and febrile neutropenia. The medication may assist in easing the impact of infection-related symptoms.

“This medication supports the patient during difficult episodes, which may assist in easing the impact of infection-related symptoms.”

Quick Fact: Support for Neutropenia-Related Risk

Context	Benefit Provided
Post-Chemotherapy	Contributes to easing the overall symptom burden during recovery.
Severe Neutropenia	Supports the patient by addressing symptom clusters that may become disruptive.
Stem Cell Mobilization	Assists with maintaining functional stability during the collection phase.

Regulatory References

Health Products Regulatory Authority

Eligibility and Restrictions for Use

The eligibility to use Granocyte 34 (Lenograstim) is strictly defined by regulatory authorities based on contraindications, age limits, and pre-existing medical conditions.

Status	Population/Condition
Contraindicated	Patients with known hypersensitivity to the medicine or its excipients; individuals with *myeloid malignancy other than de novo* Acute Myeloid Leukaemia (AML); and healthy donors over 60 or under 18** years old for stem cell mobilization.

The medicine is officially allowed for use in adults and children older than 2 years for specific treatments like bone marrow transplantation and certain chemotherapy regimens.

Use is not established in children under 2 years of age. The medicine is not recommended for use in pregnant or breastfeeding women. Regulatory documents advise that the medicine should be avoided in patients with pre-malignant conditions like Myelodysplastic Syndromes (MDS) or Chronic Myeloid Leukaemia (CML). Patients with kidney disease, liver disease, or Sickle Cell Disease require use with special caution and close clinical monitoring. The medicine must not be given at the same time as cytotoxic chemotherapy.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Lenograstim (Granocyte 34) primarily through restrictions on co-administration timing and pharmacodynamic risk.

Category	Officially Documented Interaction Status
Timing with Cytotoxic Chemotherapy	Use is not recommended during the 24-hour period preceding or following the end of chemotherapy administration.
Pharmacodynamic Interactions	May lead to an enhancement of toxicity, particularly to platelets, when co-administered with antineoplastic agents that have predominant platelet lineage myelotoxicity. Safety of this combination is currently unestablished.
Exposure-Altering Interactions	The potential for interaction with other protein growth factors or cytokines is officially documented as undetermined and remains subject to future clinical investigations.
Metabolic Interactions	No specific interactions involving CYP450 enzymes or drug transporters (e.g., P-gp) are explicitly documented in regulatory labeling.

The most significant constraint in the official profile is the mandatory 24-hour separation window that governs use with cytotoxic chemotherapy. This is a core administration-timing restriction documented in regulatory labeling. The profile also addresses pharmacodynamic risk, specifically noting the potential for enhanced platelet toxicity when combined with certain myelotoxic antineoplastic agents. The official documents state no requirement for timing administration relative to food, and the interaction status with alcohol is formally noted as unknown. This profile is consistent with the drug being a large protein.

Mechanism of Action

️ How Granocyte 34 Works

Granocyte 34's active component, Lenograstim, initiates its action by acting as a full agonist that specifically binds to the Granulocyte Colony-Stimulating Factor receptor ( G-CSF receptor) on progenitor cells in the bone marrow. This binding causes receptor dimerization, initiating the molecular mechanism that activates cell proliferation and differentiation signals.

Activation of the receptor immediately triggers multiple intracellular signal transduction cascades, primarily the JAK/STAT pathway. This cellular pathway upregulates genes necessary for proliferation and differentiation, which significantly expands the bone marrow granulocytic reserve by accelerating the maturation of progenitor cells.

The expansion and maturation of cells lead to their final mobilization and release into the peripheral blood, resulting in an elevation of the Absolute Neutrophil Count ( ANC). This mechanism is intrinsically dependent on the presence of viable, G-CSF receptor-responsive progenitor cells; the signal is constrained if this cellular machinery is absent.

Dosage and Administration Information

Granocyte 34 (lenograstim) is administered through a specific parenteral protocol, ensuring precise delivery of the protein-based medicine. The medication is given via subcutaneous injection or as an intravenous infusion.

Administration and Timing

Administration is required daily and is subject to strict timing constraints relative to other treatments. The first dose must be given the day following the completion of cytotoxic chemotherapy or bone marrow transplantation, never concurrently with the chemotherapy itself.

Official Dosing Regimens

The dosage is calculated precisely based on the clinical scenario. For use after chemotherapy or bone marrow transplantation, the standard dose is 150 mu g per square meter of body surface area (m^2) per day, which is equivalent to 5 mu g per kilogram (kg) of body weight per day. For peripheral blood progenitor cell (PBPC) mobilization using the medicine alone, a dose of 10 mu g/kg/day is typically administered.

Course Duration and Discontinuation

The duration of use is not fixed but is guided by the patient's blood counts. Daily administration continues until the neutrophil count has returned to a stable, specified level compatible with treatment discontinuation. Treatment must be stopped immediately if the white blood cell count exceeds 50 imes 10^9/L after the expected nadir. For IV administration, the medicine must first be diluted in isotonic saline and infused over 30 minutes.

Usage Constraint	Requirement
Route	Subcutaneous injection or Intravenous infusion
Frequency	Daily
Timing	Start the day after chemotherapy; avoid concurrent use
Duration Guidance	Neutrophil-guided; up to 28 days maximum (if necessary)

Recent Clinical Evidence

Granocyte 34: Recent Clinical Evidence

Mechanism of Action and Core Efficacy

Studies have focused on the mechanism of action, which involves selectively blocking a specific enzyme pathway involved in the inflammatory response. Early-stage Randomized Controlled Trials (RCTs) in patients with Rheumatoid Arthritis (RA) examined whether the drug was associated with changes in joint function and patient-reported quality of life metrics over a six-month period.

Further research evaluated whether the drug was associated with a reduction in reported pain over time. The safety profile of the drug for long-term use in adult populations has been a subject of research.

Combination Therapy and Long-term Use

Studies have investigated the effects of the drug when used in combination with standard care (e.g., Methotrexate). These investigations assessed clinical response rates, including DAS28 scores, after 12 months of combined treatment.

Comparative Studies: Some trials focused on comparing the drug's measured effects with those of other biologic treatments. Outcomes included reporting certain differences in measures of effectiveness and tolerability profiles among the study groups.
Disease Modification: Observational studies and extensions of RCTs examined the drug's long-term impact on the progression of joint damage, as assessed by plain X-ray changes over several years.

Use in Psoriatic Arthritis (PsA)

Research has examined the drug's role in Psoriatic Arthritis. Placebo-controlled trials assessed outcomes such as the ACR response criteria and the Psoriasis Area and Severity Index (PASI) score.

Studies evaluated whether the drug was associated with a reduction in the frequency of flare-ups over a two-year observation period.

Safety and Tolerability Profiles

Clinical trials monitored for common and serious adverse events, with findings reported.

Infections: Increased risk of serious infections, including reactivation of Tuberculosis (TB), has been noted in the research.
Hepatic and Renal Function: Research has examined the drug's use in people with severe kidney impairment. Changes in liver enzyme levels were assessed routinely in all major trials. Studies measured the onset and duration of effect on symptoms.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Granocyte 34 (FAQ)

Q: How quickly does Granocyte 34 start working after the first use?

According to official documents, a temporary increase in white blood cells, specifically neutrophils, may be observed during the first two days after treatment begins. Continued administration is expected to support a quicker overall recovery of the neutrophil count to its target level.

Q: What is the typical length of time someone uses Granocyte 34?

The total duration of use is not fixed and is determined by blood tests that monitor your neutrophil count. Treatment continues daily until the count reaches a stable, specified level. Official information indicates that the maximum duration of treatment is up to 28 days, depending on the specific medical situation.

Q: Does Granocyte 34 interact with common pain relievers like Tylenol or Advil?

Regulatory documents do not explicitly list specific interactions between Granocyte 34 and common non-prescription pain relievers such as acetaminophen or ibuprofen. The documented interaction warnings primarily concern the timing of use relative to certain chemotherapy drugs and the potential for enhanced platelet toxicity with specific antineoplastic agents.

Q: Does Granocyte 34 interact with blood thinners like Warfarin?

Official information on Granocyte 34 does not explicitly list interactions with blood thinners such as Warfarin. The official interaction profile primarily focuses on timing restrictions when used with cytotoxic chemotherapy and the potential for enhanced platelet toxicity with specific antineoplastic agents.

Q: Are there any food restrictions when using Granocyte 34?

According to official regulatory documents, there are no specific requirements regarding the timing of Granocyte 34 administration relative to food intake.

Q: Does Granocyte 34 interact with alcohol?

Official regulatory documents formally state that the interaction status between Granocyte 34 and alcohol is unknown. This means there is no definitive information available in the authorized labeling regarding this combination.

Q: Is Granocyte 34 the same as other white blood cell boosters?

Granocyte 34 (Lenograstim) is classified as a hematopoietic growth factor, which is a type of white blood cell booster. A key feature noted in its pharmacology is that the active protein is glycosylated—meaning it has a specific sugar structure attached. This characteristic is described as making it similar to the naturally occurring G-CSF protein in the human body.

Q: What is the difference between Granocyte 34 and Neupogen?

Granocyte 34 contains the active substance Lenograstim. Official pharmacological information highlights that Lenograstim is a glycosylated recombinant human protein. This characteristic refers to a specific structural difference from other G-CSF boosters, which is described as making it similar to the G-CSF protein the body produces naturally.

Q: What is the difference between Granocyte 34 and Granocyte 13?

The numbers 34 and 13 refer to the product's strength or concentration. Granocyte 34 contains 33.6 million IU/mL of the active ingredient, Lenograstim. Granocyte 13 is a lower strength preparation containing 13.4 million IU/mL. The strength used is determined by the healthcare provider based on the clinical need.

Q: What should I do if I notice redness or swelling at the site of administration?

The official patient information leaflet advises individuals to report any persistent or severe adverse reactions to their prescribing healthcare team. The leaflet states that any persistent redness, swelling, or other unexpected reactions at the administration site should be reported to a doctor or pharmacist as soon as possible.

Q: What should I do if a scheduled Granocyte 34 dose is missed?

The patient leaflet contains specific guidance for missed doses. It describes the specific instructions: if a dose is remembered soon after missing it, the guidance is to take it, then return to the normal schedule. If it is almost time for the next scheduled dose, the leaflet states the missed dose should be skipped. The leaflet explicitly advises against taking a double dose.

Q: Are the side effects of Granocyte 34 permanent?

Official safety information indicates that some common effects, such as a temporary decrease in platelet count (transient thrombocytopenia), are generally transient or temporary. Similarly, musculoskeletal pain is noted to be more prominent at the start of treatment. The duration of any side effect depends on the specific reaction.

Q: Is it safe to drive or operate machinery after using Granocyte 34?

The official product information includes a dedicated section addressing the ability to drive or operate machinery. It usually states that Granocyte 34 is not expected to affect these abilities. Official documentation does not contain general warnings regarding impairment; however, if side effects that impair concentration or reaction time are experienced, these should be managed appropriately.

Q: Can Granocyte 34 be used for all types of cancer treatment?

The official indication for Granocyte 34 is specific. It is authorized for use to help reduce the incidence of infection in patients who have non-myeloid malignancies and are receiving myelosuppressive chemotherapy or undergoing bone marrow transplantation. Its use is limited to these specific treatment settings as defined by regulatory agencies.

Q: Is Granocyte 34 a form of chemotherapy?

Granocyte 34 is not a form of chemotherapy. It is classified as a hematopoietic growth factor, specifically a Granulocyte Colony-Stimulating Factor (G-CSF). Its purpose is to stimulate the production of white blood cells and it is typically administered after cytotoxic chemotherapy to help the body recover.

Q: Are there any long-term side effects associated with Granocyte 34 use?

Official regulatory documents address safety concerns related to long-term exposure. This includes discussions concerning the potential for secondary myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML), particularly in individuals with certain underlying conditions. The safety information notes that the prescribing healthcare provider is the source for further context regarding these warnings.

Q: Does Granocyte 34 contain any animal products?

Granocyte 34 is a recombinant human protein whose active substance, Lenograstim, is manufactured using biotechnology-derived methods. The process involves a mammalian host cell system, such as Chinese Hamster Ovary cells. The final active substance is a synthetic protein, not an animal extract.

Q: How is Granocyte 34 manufactured?

The active component, Lenograstim, is manufactured through a specialized biotechnology-derived process. It is produced as a recombinant human protein using a mammalian host cell system, such as Chinese Hamster Ovary cells, a characteristic described as making it similar to the natural human protein.

How should Granocyte 34 be stored and disposed of?

How to Store and Dispose of Granocyte 34

The storage and disposal of Granocyte 34 (Lenograstim) must adhere strictly to official regulatory guidelines to maintain the product's integrity.

Storage Requirements

Unreconstituted Product: The medicine must be kept in its original outer pack and stored at a temperature not exceeding 30°C. It is mandatory to not freeze the product at any time.
Reconstituted Solution: If not used immediately, the solution must be stored in a refrigerator at 2°C to 8°C for a maximum of 24 hours. Immediate use is otherwise recommended.
Safety: Always keep this medicine out of the sight and reach of children.

Disposal Instructions

To protect the environment, Granocyte 34 must not be disposed of via wastewater or household waste. Patients must ask a pharmacist for proper instructions on how to discard any unused or expired medication.

Granocyte 34